Kiniksa Pharmaceuticals (NASDAQ:KNSA) PT Raised to $30.00

Kiniksa Pharmaceuticals (NASDAQ:KNSA) had its price objective lifted by Evercore ISI from $25.00 to $30.00 in a report issued on Wednesday, Benzinga reports. The firm currently has an outperform rating on the stock.

KNSA has been the topic of several other research reports. TheStreet upgraded shares of Kiniksa Pharmaceuticals from a d+ rating to a c rating in a research note on Thursday, February 29th. Wedbush reiterated an outperform rating and issued a $30.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, April 23rd.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock opened at $17.88 on Wednesday. The firm has a market cap of $1.26 billion, a PE ratio of 162.56, a P/E/G ratio of 5.59 and a beta of 0.27. The firm’s 50 day moving average price is $19.23 and its two-hundred day moving average price is $18.01. Kiniksa Pharmaceuticals has a twelve month low of $10.65 and a twelve month high of $22.09.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, April 23rd. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.11). The company had revenue of $79.90 million during the quarter, compared to analyst estimates of $76.97 million. Kiniksa Pharmaceuticals had a net margin of 2.78% and a negative return on equity of 7.32%. The firm’s quarterly revenue was up 65.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.18) EPS. Equities analysts anticipate that Kiniksa Pharmaceuticals will post -0.04 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals

In other news, CAO Michael R. Megna sold 5,126 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total transaction of $111,695.54. Following the transaction, the chief accounting officer now owns 17,588 shares in the company, valued at approximately $383,242.52. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CAO Michael R. Megna sold 9,659 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $21.45, for a total value of $207,185.55. Following the transaction, the chief accounting officer now directly owns 17,588 shares in the company, valued at approximately $377,262.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Michael R. Megna sold 5,126 shares of the firm’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total transaction of $111,695.54. Following the completion of the transaction, the chief accounting officer now owns 17,588 shares in the company, valued at $383,242.52. The disclosure for this sale can be found here. Insiders have sold a total of 33,109 shares of company stock worth $709,929 in the last 90 days. 54.23% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KNSA. Altitude Crest Partners Inc. acquired a new position in Kiniksa Pharmaceuticals in the 4th quarter valued at $7,999,000. Peregrine Capital Management LLC acquired a new position in Kiniksa Pharmaceuticals in the 1st quarter valued at $4,657,000. Acadian Asset Management LLC grew its stake in Kiniksa Pharmaceuticals by 916.6% in the 3rd quarter. Acadian Asset Management LLC now owns 226,181 shares of the company’s stock valued at $3,919,000 after buying an additional 203,933 shares during the last quarter. Granahan Investment Management LLC grew its stake in Kiniksa Pharmaceuticals by 35.2% in the 4th quarter. Granahan Investment Management LLC now owns 722,388 shares of the company’s stock valued at $12,671,000 after buying an additional 188,174 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its stake in Kiniksa Pharmaceuticals by 180.1% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 208,500 shares of the company’s stock valued at $3,622,000 after buying an additional 134,070 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.